```
=> d que stat l17
L1             1 SEA FILE=REGISTRY ABB=ON  443-48-1/RN
L2             1 SEA FILE=REGISTRY ABB=ON  19387-91-8/RN
L13          387 SEA FILE=HCAPLUS ABB=ON  (L1 OR ?METRONIDAZOL?) AND (L2 OR
                 ?TINIDAZOL?)
L14        50955 SEA FILE=HCAPLUS ABB=ON  (?SKIN?(W)(?DISEAS? OR ?BLOTCH? OR
                 ?PIGMENT? OR ?SCAR?) OR ?DERMAT? OR ?ATOPIC?(W)?DERMAT? OR
                 ?PSORIAS? OR ?HIRCUS? OR ?BODY?(W)?ODOR? OR ?OSMIDROS? OR
                 ?INSECT?(W)?BITE? OR ?DERM?(W)?PRURIT? OR ?DRUG?(W)?RASH? OR
                 ?CHILBLAIN? OR ?CHILLBLAIN? OR ?ERYTHRODERM? OR ?TINEA?)
L15       223597 SEA FILE=HCAPLUS ABB=ON  (?PRESS?(W)?SORE? OR ?WOUND? OR
                 ?PALMOPLAN?(W)?PUSTUL? OR ?LICHEN?(W)(?PLAN? OR ?NITID?) OR
                 ?PITYRIAS?(W)?RUBRA?(W)?PILAR? OR ?PITYRIAS?(W)?ROSEA? OR
                 ?ERYTHEM? OR ?TOXIC?(W)?RASH? OR ?ALOPECIA? OR ?BURN? OR
                 ?KELOID?)
L16         4611 SEA FILE=HCAPLUS ABB=ON  (?PEMPHIG? OR ?SEBORRH? OR ?DERM?(W)?S
                 TOMATIT? OR ?CANDIDIAS? OR ?INTERDIG?(W)?EROSION? OR ?INTERTRIG
                 ? OR ?INFANT?(W)?PARASIT?(W)?ERYTHEM? OR ?PERIONYCH? OR
                 ?TINEA?(W)?VERSICOLOR?)
L17           19 SEA FILE=HCAPLUS ABB=ON  L13 AND (L14 OR L15 OR L16)

=> d ibib abs hitrn 1-19

L17  ANSWER 1 OF 19  HCAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:        2003:171216  HCAPLUS
TITLE:                   Effects of metronidazole and
                         tinidazole ointments on models for
                         inflammatory dermatitis in mice
AUTHOR(S):               Nishimuta, K.; Ito, Y.
CORPORATE SOURCE:        Graduate School of Medical Sciences, Department of
                         Pharmacology, Kyushu University, Fukuoka, 812-8582,
                         Japan
SOURCE:                  Archives of Dermatological Research (2003), 294(12),
                         544-551
                         CODEN: ADREDL; ISSN: 0340-3696
PUBLISHER:               Springer-Verlag
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   We investigated the effects of 1-4% ointments of metronidazole
     and tinidazole (derivs. of nitroimidazole) on models of
     inflammatory dermatitis evoked by antigen, hapten and monoclonal
     anti-dinitrophenol (DNP) IgE antibody in mice. Metronidazole
     and tinidazole ointments (1) suppressed the late-phase reaction
     (LPR) of biphasic ear edema in mice sensitized with ovalbumin (OA), (2)
     suppressed trinitrochlorobenzene-induced inflammatory dermatitis
     , (3) suppressed the immediate phase reactions and LPR in mice passively
     sensitized with anti-DNP IgE mAb, and (4) enhanced vascular permeability
     and the no. of scratching reactions, presumably due to itching, in
     passively sensitized mice. These results strongly indicate that
     metronidazole and tinidazole 1-4% ointments possess
     antiinflammatory, immunosuppressive and anti-itching effects, and have the
     potential for clin. use in the treatment of human inflammatory
     skin diseases including atopic
     dermatitis in addn. to rosacea and acne vulgaris.

L17  ANSWER 2 OF 19  HCAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:        2002:905722  HCAPLUS
DOCUMENT NUMBER:         137:389155
TITLE:                   Novel topical microbicidal compositions
```

INVENTOR(S): Mody, Shirish Bhagwanlal; Doshi, Madhukant Mansukhlal; Joshi, Milind Dattatraya
PATENT ASSIGNEE(S): J.B. Chemicals & Pharmaceuticals Ltd., India
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094179	A2	20021128	WO 2002-IN120	20020516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

PRIORITY APPLN. INFO.: IN 2001-MU483 A 20010523

AB A pharmaceutical compn. for topical application and manufg. process thereof for treatment of microbial and mycotic infections caused by aerobic and anaerobic microorganisms comprises **metronidazole** and Povidone-Iodine. Such a compn. can be administered topically to patients in various pharmaceutical dosage forms. Thus, a compn. contained **metronidazole** 1.00, Povidone-iodine 5.00, PEG-4000 30.00, PEG-400 59.75, and water 4.25%.

IT **443-48-1, Metronidazole**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical microbicidal compns.)

IT **19387-91-8, Tinidazole**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical microbicidal compns.)

L17 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:638143 HCAPLUS
DOCUMENT NUMBER: 137:174963
TITLE: **Wound** healing compositions containing zinc oxide and fat-soluble vitamins
INVENTOR(S): Peshoff, Mickey L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 689,087.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002114847	A1	20020822	US 2002-125165	20020418

PRIORITY APPLN. INFO.: US 2000-689087 A2 20001012

AB This invention pertains to therapeutic antibacterial/antifungal **wound** healing compns. comprising a therapeutically effective amt. of antibacterial agents and/or antifungal agents and/or **wound** healing compn. alone. The **wound** healing compn. comprises (a) zinc oxide and (b) fat-sol. vitamins. The therapeutic antibacterial/antifungal **wound** healing compns. may be utilized

in a wide variety of pharmaceutical products. This invention also relates to methods for prepg. and using the antibacterial/antifungal **wound** healing compns. and the pharmaceutical products in which the therapeutic compns. may be used.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibacterial/antifungal **wound** healing compns. contg. zinc oxide and fat-sol. vitamins)

L17 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:521462 HCAPLUS
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrens and compounds in treatment for inhibiting neoplastic lesions and microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
WO 2002053138	A3	20020919		

W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IE 2001-2 A 20010102
OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immundysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixt. showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further contg.; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

L17 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:327820 HCAPLUS
DOCUMENT NUMBER: 136:345790
TITLE: Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate Helicobacter pylori as a concomitant treatment for peptic ulcers and other gastrointestinal diseases
INVENTOR(S): Athanikar, Narayan
PATENT ASSIGNEE(S): Josman Laboratories, USA
SOURCE: U.S., 16 pp., Cont.-in-part of U.S. 5,972,267.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6379651	B1	20020430	US 1999-364613	19990729
ZA 9600099	A	19970708	ZA 1996-99	19960108
IL 117751	A1	20010826	IL 1996-117751	19960401
US 6372784	B1	20020416	US 2000-524891	20000314
US 6426085	B1	20020730	US 2000-578824	20000524

PRIORITY APPLN. INFO.:
US 1995-385060 A2 19950207
US 1995-518971 B1 19950824
US 1997-827566 B1 19970328
US 1998-50643 A2 19980330
JP 1994-93518 A 19940502
US 1996-594148 B1 19960131
US 1997-918322 B1 19970826
US 1998-80583 B1 19980518
US 1999-253559 B1 19990219
US 1999-363077 B1 19990728

AB The invention relates to concomitant treatment with bismuth compds., e.g., colloidal bismuth subcitrate, bismuth salicylate, bismuth subnitrate, bismuth subcarbonate, bismuth tartrate, bismuth subgallate, etc., other antibacterial compds., and/or antibiotics, e.g., tetracycline, amoxycillin, ampicillin, doxycycline, erythromycin, clarithromycin, **metronidazole**, **tinidazole**, ciprofloxacin, etc., in oral-topical and peroral dosage forms to eradicate H. pylori from its niches both in the dental plaque and in the gastric mucosa in order to improve the cure rate of peptic ulcer and prevent ulcer relapse. The invention further provides for treatment with bismuth compds., other antibacterial compds., and/or antibiotics which are effective against Campylobacter rectus and Treponema denticola which are responsible for causing halitosis. The invention also provides bismuth compds. which have applications in **wound** healing, particularly in ocular and dermal **wound** healing. For example, patients with pos. response for the presence of H. pylori in the dental plaque/oral cavity were given either a placebo chewing gum or a chewing gum contg. antibiotic/antibacterial (10-50 mg per piece of gum). The group receiving the chewing guru contg. antibiotic/antibacterial showed significantly lower incidence of H. pylori presence in the dental plaque/saliva compared to placebo chewing gum group after 2 and 4 wk of treatment.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral-topical delivery of antibacterials/antibiotics and bismuth compds. to eradicate Helicobacter pylori as treatment for peptic ulcers and other gastrointestinal diseases)

REFERENCE COUNT: 232 THERE ARE 232 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:63827 HCAPLUS
DOCUMENT NUMBER: 134:120957
TITLE: Nitroimidazole external preparations for **dermatosis**

INVENTOR(S): Nishimuta, Nishizumi; Nishimuta, Kazuhiro
PATENT ASSIGNEE(S): Shoei Co., Ltd., Japan
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005400	A1	20010125	WO 2000-JP4728	20000714
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001048785	A2	20010220	JP 2000-216886	19990721
JP 3193028	B2	20010730		
JP 2001163781	A2	20010619	JP 2000-206175	20000707
JP 2001163782	A2	20010619	JP 2000-206176	20000707
JP 2001270826	A2	20011002	JP 2000-206177	20000707
JP 2001288082	A2	20011016	JP 2000-206178	20000707
EP 1206937	A1	20020522	EP 2000-946319	20000714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2001089371	A2	20010403	JP 2000-216912	20000718
JP 3187806	B2	20010716		
JP 2001288083	A2	20011016	JP 2000-220650	20000721
JP 2001288084	A2	20011016	JP 2000-220651	20000721
JP 2001288085	A2	20011016	JP 2000-220652	20000721
JP 2001288086	A2	20011016	JP 2000-220653	20000721

PRIORITY APPLN. INFO.:
JP 1999-234496 A 19990716
JP 1999-206508 A 19990721
JP 1999-271077 A 19990924
JP 1999-312840 A 19990928
JP 2000-42012 A 20000114
JP 2000-67746 A 20000204
WO 2000-JP4728 W 20000714

OTHER SOURCE(S): MARPAT 134:120957

AB External prepns. for the treatment of **dermatosis** comprise nitroimidazole derivs. An ointment was formulated contg. **metronidazole** 2, Tween 80 1, propylene glycol 28, and white vaseline 69 parts. The ointment was clin. tested with **atopic dermatitis** patients.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. contg. nitroimidazole derivs. for treatment of **dermatosis**)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:516745 HCAPLUS
DOCUMENT NUMBER: 131:297353

TITLE: Nitazole-antimicrobial substance
AUTHOR(S): Kalinichenko, N. F.
CORPORATE SOURCE: I. I. Mechnikov Kharkov Research Institute of Microbiology and Immunology, Russia
SOURCE: Mikrobiologichnii Zhurnal (1998), 60(1), 83-91
CODEN: MIZHEY; ISSN: 0201-8462
PUBLISHER: Institut Mikrobiologii i Virusologii NAN Ukraini
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Russian

AB A review with 51 refs. The antibacterial activity of protistocide drug nitazole has been revealed for the first time in the 80's at the Lab. of Clin. Microbiol. of the Mechnikov Research Institute of Microbiol. and Immunol. Unlike other imidazoles, such as **metronidazole** and **tinidazole**, nitazole acts as the inhibitor of growth of Gram pos. facultative and obligate anaerobic microorganisms as well as Gram negatives except for Pseudomonas aeruginosa and Proteus. Nitazole, as a main antimicrobial agent of many multicomponent drugs which are created on the hydrophilic basis (matrixes), is particularly useful for topical treatment of **wounds** and **burns** in the first and second phases of these processes. Drugs which include nitazole possess not only antibacterial and protistocide activity but also act as antiinflammatory, **wound** heeling ones and have osmotic property. These drugs are approved by the Ukrainian Ministry of Public Health for wide use in surgical, gynecol., proctol. and **dermatol.** clinics as well as in combustol.

L17 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:194002 HCAPLUS
DOCUMENT NUMBER: 130:232488
TITLE: Bioreductive compounds for treatment of inflammatory conditions
INVENTOR(S): Adams, Ged; Naughton, Declan; Stratford, Ian
PATENT ASSIGNEE(S): Theramark Limited, UK; Adams, Margaret; Blake, David
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912548	A1	19990318	WO 1998-GB2661	19980908
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9890827	A1	19990329	AU 1998-90827	19980908

PRIORITY APPLN. INFO.:		
GB 1997-19059	A	19970908
GB 1997-19061	A	19970908
GB 1998-18027	A	19980819
WO 1998-GB2661	W	19980908

AB A bioreductive compd., e.g., a 2- or 5-nitroimidazole, a quinone, an arom. nitro compd., an enamine, a lactone, a lactam, etc., or a pharmaceutically acceptable salt thereof, is used for the treatment of inflammatory conditions assocd. with hypoxia and/or ischemia. Examples of inflammatory

conditions which may be treated in accordance with the invention include inflammation resulting from or are present in certain forms of diabetes, stroke, sepsis, Alzheimer's and other neurol. diseases or disorders, cancer, kidney, digestive, and liver diseases, transplantation, **wound** healing, fibrotic disorders, cardiovascular or cerebral reperfusion injury, cystic fibrosis, **psoriasis**, ulcers, AIDS, ulcerative colitis, and inflammatory bowel disease. The bioreductive compd. is capable of targeting tissues having an enhanced reductase activity. Misonidazole or **metronidazole** (1, 5, 10, and 20 mg) was able to target and kill hypoxic cells during the inflammatory response in a rat model of inflammation, as indicated by increases in pyknotic index. The bioreductive drug significantly inhibited proliferation of an air pouch. Misonidazole was most effective on days 2 and 3 when the pouch was hypoxic. Tablets and capsules each contg. nimorazole 60 and 250 mg, resp., were prepd.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioreductive compds. for treatment of inflammatory conditions assocd. with hypoxia and/or ischemia)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:136777 HCAPLUS
DOCUMENT NUMBER: 130:200931
TITLE: Therapeutic permeation enhanced-**wound** healing compositions containing antioxidant and lactate and fatty acids
INVENTOR(S): Martin, Alain
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 224,936, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5874479	A	19990223	US 1998-19457	19980205
JP 2002356421	A2	20021213	JP 2002-82387	19920115
ZA 9502911	A	19960828	ZA 1995-2911	19950407
US 5981606	A	19991109	US 1998-19316	19980205
PRIORITY APPLN. INFO.:			US 1991-663500	B1 19910301
			US 1993-53922	B2 19930426
			US 1994-224936	B2 19940408
			JP 1992-505329	A3 19920115
			US 1997-37730P	P 19970202

AB This invention pertains to therapeutic **wound** healing compns. for protecting and resuscitating mammalian cells. This invention also pertains to therapeutic permeation enhanced-**wound** healing compns. for enhancing the penetration of actives into membranes and increasing the proliferation and resuscitation rate of mammalian cells. The therapeutic **wound** healing compn. comprises pyruvate, an antioxidant, lactate, permeation enhancer, and a mixt. of satd. and unsatd. fatty acids. This invention also pertains to methods for prepg.

and using the permeation enhanced-**wound** healing compns. and the topical and ingestible pharmaceutical products in which the therapeutic compns. may be used. Thus, a **wound** healing compn. was obtained from sodium pyruvate 2, vitamin E 1, chicken fat 2, LYCD 2400 U, shark liver oil 3, petrolatum 64, paraffin 5, and emulsifier 0.2%.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic permeation enhanced-**wound** healing compns. contg. antioxidant and lactate and fatty acids)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:69901 HCAPLUS
DOCUMENT NUMBER: 130:144180
TITLE: Antibacterial **wound** healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain
PATENT ASSIGNEE(S): Warner Lambert Company, USA
SOURCE: U.S., 41 pp., Cont.-in-part of U.S. Ser. No. 53,922, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5863938	A	19990126	US 1995-446963	19950522
JP 2002356421	A2	20021213	JP 2002-82387	19920115
CA 2218619	AA	19961128	CA 1996-2218619	19960426
WO 9637228	A1	19961128	WO 1996-US5897	19960426
W: AU, CA, JP, MX, NZ, SG				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9657885	A1	19961211	AU 1996-57885	19960426
AU 711789	B2	19991021		
EP 828515	A1	19980318	EP 1996-914561	19960426
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
NZ 308293	A	20000128	NZ 1996-308293	19960426
JP 2001501576	T2	20010206	JP 1996-535670	19960426
US 5981606	A	19991109	US 1998-19316	19980205

PRIORITY APPLN. INFO.:

US 1991-663500	B1	19910301
US 1993-53922	B2	19930426
JP 1992-505329	A3	19920115
US 1994-224936	B1	19940408
US 1995-446963	A	19950522
WO 1996-US5897	W	19960426
US 1997-37730P	P	19970202

AB This invention pertains to therapeutic antibacterial-**wound** healing compns. The compns. comprise a therapeutically effective amt. of an antibacterial agent and a **wound** healing compn. In one embodiment the **wound** healing compn. comprises (a) pyruvate; (b) an antioxidant; and (c) a mixt. of satd. and unsatd. fatty acids. The therapeutic antibacterial-**wound** healing compns. may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for prepg. and using the therapeutic antibacterial-**wound** healing compns. and the pharmaceutical products in which the therapeutic compns. may be used. A **wound** healing compn. contg.

Na pyruvate 2, vitamin E 1, chicken fat 2 %, LYCD (live yeast cell deriv.) 2400 IU, shark liver oil 3, petrolatum 64, mineral oil 22.53, paraffins 5, and an emulsifier 0.2 %, was applied on the incised parts of mice to demonstrate **wound** healing effects.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibacterial **wound** healing compns. contg. pyruvate and antioxidant and fatty acid)

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:479396 HCAPLUS
DOCUMENT NUMBER: 129:100054
TITLE: A nitroimidazole gel composition
INVENTOR(S): Goodman, Michael; Lindahl, Ake
PATENT ASSIGNEE(S): Bioglan Ireland (R & D) Ltd., Ire.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827960	A2	19980702	WO 1997-GB3512	19971219
WO 9827960	A3	19980911		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9853308	A1	19980717	AU 1998-53308	19971219
AU 730812	B2	20010315		
ZA 9711455	A	19980902	ZA 1997-11455	19971219
EP 946143	A2	19991006	EP 1997-950300	19971219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
NZ 336258	A	20010427	NZ 1997-336258	19971219
JP 2001507018	T2	20010529	JP 1998-528544	19971219
NO 9902980	A	19990816	NO 1999-2980	19990617
US 6348203	B1	20020219	US 2000-331367	20000616

PRIORITY APPLN. INFO.: GB 1996-26513 A 19961220
WO 1997-GB3512 W 19971219

AB A viscous hydrogel compn. for topical treatment of a skin condition involving dry or inflamed skin, comprises an antimicrobial nitroimidazole drug, a water miscible alkylene glycol, a hydroxyalkyl cellulose gelling agent and water, buffered to have a physiol. acceptable pH. Thus, a gel contained **metronidazole** 0.75, hydroxyethyl cellulose 1.8, propylene glycol 1.8, propylene glycol 5.0, Me p-hydroxybenzoate 0.15, Pr p-hydroxybenzoate 0.05, citric acid and sodium citrate qs to pH 5.5, and water to 100%.

IT **443-48-1, Metronidazole**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(nitroimidazole gel compn.)
IT **19387-91-8, Tinidazole**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitroimidazole gel compn.)

L17 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:574520 HCAPLUS
DOCUMENT NUMBER: 127:225309
TITLE: Bioadhesive-**wound** healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain; Leung, Sau-hung S.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 131 pp., Cont.-in-part of U.S. Ser. No. 298,521, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5658956	A	19970819	US 1995-445824	19950522
JP 2002356421	A2	20021213	JP 2002-82387	19920115
CA 2194876	AA	19960307	CA 1995-2194876	19950707
WO 9606640	A1	19960307	WO 1995-US8568	19950707
W: AU, CA, JP, MX, NZ, SG				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9530045	A1	19960322	AU 1995-30045	19950707
AU 707353	B2	19990708		
EP 779820	A1	19970625	EP 1995-926209	19950707
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
JP 10505057	T2	19980519	JP 1996-508729	19950707
NZ 290031	A	20010223	NZ 1995-290031	19950707
ZA 9507245	A	19970630	ZA 1995-7245	19950829
US 5981606	A	19991109	US 1998-19316	19980205

PRIORITY APPLN. INFO.:

US 1991-663500	B1	19910301
US 1993-53922	B2	19930426
US 1994-298521	B2	19940830
JP 1992-505329	A3	19920115
US 1994-224936	B1	19940408
US 1995-445824	A	19950522
WO 1995-US8568	W	19950707
US 1997-37730P	P	19970202

AB The present invention pertains to therapeutic bioadhesive-**wound** healing compns. useful for treating **wounds** and increasing the proliferation and resuscitation rate of mammalian cells. The compns. comprise a bioadhesive agent and a therapeutically effective amt. of a **wound** healing compn. In one embodiment the **wound** healing compn. comprises (a) pyruvate; (b) an antioxidant; and (c) a mixt. of satd. and unsatd. fatty acids. The therapeutic bioadhesive-**wound** healing compns. may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-**wound** healing compns. may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for prepg. and using the bioadhesive-**wound** healing compns. and the pharmaceutical products in which the compns. may be used.
IT **443-48-1, Metronidazole 19387-91-8,**

Tinidazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioadhesive **wound** healing compns.)

L17 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:67454 HCAPLUS
DOCUMENT NUMBER: 126:79960
TITLE: Antibacterial-**wound** healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9637228	A1	19961128	WO 1996-US5897	19960426
W: AU, CA, JP, MX, NZ, SG				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5863938	A	19990126	US 1995-446963	19950522
AU 9657885	A1	19961211	AU 1996-57885	19960426
AU 711789	B2	19991021		
EP 828515	A1	19980318	EP 1996-914561	19960426
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
NZ 308293	A	20000128	NZ 1996-308293	19960426
JP 2001501576	T2	20010206	JP 1996-535670	19960426

PRIORITY APPLN. INFO.:
US 1995-446963 A 19950522
US 1991-663500 B1 19910301
US 1993-53922 B2 19930426
WO 1996-US5897 W 19960426

AB This invention pertains to therapeutic antibacterial-**wound** healing compns. The compns. comprise a therapeutically effective amt. of an antibacterial agent and a **wound** healing compn. In one embodiment the **wound** healing compn. comprises (a) pyruvate; (b) an antioxidant; and (c) a mixt. of satd. and unsatd. fatty acids. The therapeutic antibacterial-**wound** healing compns. may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for prepg. and using the therapeutic antibacterial-**wound** healing compns. and the pharmaceutical products in which the therapeutic compns. may by used.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibacterial **wound** healing compns.)

L17 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:367739 HCAPLUS
DOCUMENT NUMBER: 125:19043
TITLE: Bioadhesive-**wound** healing composition
INVENTOR(S): Leung, Sau-Hung S.; Martin, Alain
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9606640	A1	19960307	WO 1995-US8568	19950707
W: AU, CA, JP, MX, NZ, SG				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5658956	A	19970819	US 1995-445824	19950522
AU 9530045	A1	19960322	AU 1995-30045	19950707
AU 707353	B2	19990708		
EP 779820	A1	19970625	EP 1995-926209	19950707
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
JP 10505057	T2	19980519	JP 1996-508729	19950707
ZA 9507245	A	19970630	ZA 1995-7245	19950829

PRIORITY APPLN. INFO.:

US 1994-298521	A	19940830
US 1995-445824	A	19950522
US 1991-663500	B1	19910301
US 1993-53922	B2	19930426
WO 1995-US8568	W	19950707

AB The present invention pertains to therapeutic bioadhesive-**wound** healing compns. useful for treating **wounds** and increasing the proliferation and resuscitation rate of mammalian cells. The compns. comprise a bioadhesive agent and a therapeutically effective amt. of a **wound** healing compn. In one embodiment the **wound** healing compn. comprises (a) pyruvate; (b) an antioxidant; and (c) a mixt. of satd. and unsatd. fatty acids. The therapeutic bioadhesive-**wound** healing compns. may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-**wound** healing compns. may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for prepg. and using the bioadhesive-**wound** healing compns. and the pharmaceutical products in which the compns. may be used.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioadhesive, topical **wound** healing compns. contg. pyruvates, antioxidants, and fatty acids)

L17 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:74132 HCAPLUS
DOCUMENT NUMBER: 124:165201
TITLE: **Wound** healing profiles of ketorolac, **metronidazole** and **tinidazole** administered post-surgically
AUTHOR(S): Prasad, D; Rao, C Mallikarjuna
CORPORATE SOURCE: Department Pharmacology, Kasturba Medical College, Manipal, 576 119, India
SOURCE: Indian Journal of Experimental Biology (1995), 33(11), 845-7
CODEN: IJEBA6; ISSN: 0019-5189
PUBLISHER: Publications & Information Directorate, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English

AB On dead space **wounds**, drugs (ketorolac, **metronidazole** and **tinidazole**) caused a significant ($P < 0.01$) decrease in breaking strength, granulation tissue wt. and hydroxyproline content in male rats. Both the parameters of excision **wound** were significantly ($P < 0.01$) hastened by **metronidazole** and **tinidazole** only. Post operative management of **wounds**

with ketorolac (a potent analgesic), **metronidazole** and **tinidazole** (for anaerobic infections) may be delt with the risk of a delay in healing. Both **metronidazole** and **tinidazole** promote the epithelization process.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(post-surgical **wound** healing profiles of ketorolac, **metronidazole**, and **tinidazole**)

L17 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:38156 HCAPLUS
DOCUMENT NUMBER: 120:38156
TITLE: Potentiation of antimicrobial effects with lauric acid and monomyristic acid monoglycerides
INVENTOR(S): Oelund, Karin; Lutz, Lena Karin; Bryland, Richard; Lindahl, Aake
PATENT ASSIGNEE(S): Hydro Pharma Sverige AB, Swed.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9320812	A1	19931028	WO 1993-SE275	19930331
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
SE 9201187	A	19931015	SE 1992-1187	19920414
SE 500777	C2	19940829		
AU 9339639	A1	19931118	AU 1993-39639	19930331
EP 636024	A1	19950201	EP 1993-909105	19930331
EP 636024	B1	19990623		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07505880	T2	19950629	JP 1993-518221	19930331
AT 181502	E	19990715	AT 1993-909105	19930331
ES 2132230	T3	19990816	ES 1993-909105	19930331
US 5550145	A	19960827	US 1994-307763	19940927
PRIORITY APPLN. INFO.:			SE 1992-1187	19920414
			WO 1993-SE275	19930331

AB An antimicrobial compn. comprises an antimicrobially effective amt. of a combination of (A) a monoglyceride of lauric acid, a monoglyceride of monomyristic acid, or a mixt. of these monoglycerides; (B) .gtoreq.1 of: i) a local anesthetic of the amide type, ii) carbamide, iii) an antibacterial substance in the form of a steroid antibiotic, an imidazole deriv., or a nitroimidazole deriv., and i.v.) a C3-6 diol; and (C) optionally, a conventional physiol. acceptable carrier and/or physiol. acceptable additives. This compn. is prepd. by heating (A) to the transition temp. of the lipid, adding (B), and optionally (C), and cooling the mixt. to form a solid lipid crystal compn. The compn. is useful for the prepn. of a **dermatol**. prepn. for combating bacteria or fungi or as a preservative additive in a cosmetic product, a food product, or a medical product. A prepn. contg. 1-glycerol monolaurate 5.5, 1-glycerol monomyristate 16.5, lidocaine 5, propylene glycol 5, and water to 100 wt.% was prepd. The prepn. was tested in a Kelsey Test in which it proved to

be very active against both bacteria and fungi. Effects on the replication of the HSV1 and 2 viruses were also demonstrated.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: BIOL (Biological study)
(antimicrobial compn. contg. potentiating lauric acid monoglyceride and/or monomyristic acid monoglyceride and)

L17 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:139824 HCAPLUS
DOCUMENT NUMBER: 118:139824
TITLE: Bismuth subsalicylate in antimicrobial treatment of patients at risk for Clostridium difficile infection
INVENTOR(S): Whalen, Scott Donald
PATENT ASSIGNEE(S): Procter and Gamble Co., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9301818	A1	19930204	WO 1992-US5848	19920715
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
CA 2113614	AA	19930204	CA 1992-2113614	19920715
AU 9223243	A1	19930223	AU 1992-23243	19920715
EP 595890	A1	19940511	EP 1992-915528	19920715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
BR 9206300	A	19940802	BR 1992-6300	19920715
JP 06509340	T2	19941020	JP 1992-502889	19920715
PRIORITY APPLN. INFO.:			US 1991-735400	19910724
			WO 1992-US5848	19920715

AB Methods for treating infected patients with antimicrobial agents when the patients are at risk for C. difficile infection comprise concurrently orally administering before the end of .apprx.5 days of antimicrobial therapy a safe and effective amt. of Bi subsalicylate (I). An elderly nursing home patient suffering from a respiratory tract infection and in a facility known to increase the patient's risk to C. difficile infection is treated with 10 days of orally administered amoxycillin (500 mg; 3 times/day) and concurrently for the same 10 days and continuing thereafter for a total of 3 wk, orally administered I (525 mg; 4 times/day). The course of treatment is completed with resoln. of the infection.

IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: BIOL (Biological study)
(bismuth subsalicylate adjunct for, for treatment of patients at risk for Clostridium difficile infection)

L17 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1992:400277 HCAPLUS
DOCUMENT NUMBER: 117:277
TITLE: Mechanism of allergic cross-reactions. I. Multispecific binding of ligands to a mouse monoclonal anti-DNP IgE antibody
AUTHOR(S): Varga, Janos M.; Kalchschmid, Gertrud; Klein, Georg

F.; Fritsch, Peter
CORPORATE SOURCE: Dep. Dermatol., Univ. Innsbruck, Innsbruck, 6020, Austria
SOURCE: Molecular Immunology (1991), 28(6), 641-54
CODEN: MOIMD5; ISSN: 0161-5890
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A recently developed solid-phase binding assay was used to investigate the specificity of ligand binding to a mouse monoclonal anti-dinitrophenyl IgE (I). All DNP-amino acids, that were tested inhibited the binding of the radio-labeled I to DNP covalently attached to polystyrene microplates; however, the concn. for 50% inhibition varied within four orders of magnitude, DNP-L-serine being the most and DNP-L-proline the least potent inhibitor. In addn. to DNP analogs, a large no. of drugs and other compds. were tested for their ability to compete with DNP for the binding site of I. At the concn. used for screening, 59% of compds. had no significant inhibition; 19% inhibited the binding of I more than 50%. Several families of compds. (tetracyclines, polymyxins, phenothiazines, salicylates, and quinones) that were effective competitors were found. Within these families, changes in the functional groups attached to the family stem had major effects on the affinity of ligand binding. The occurrence frequencies of interactions of ligands with I is in good agreement with the semi-empirical model for multispecific antibody-ligand interactions.
IT **443-48-1, Metronidazole 19387-91-8, Tinidazole**
RL: BIOL (Biological study)
(binding of, to anti-dinitrophenol monoclonal antibody, allergic cross-reaction mechanism in relation to)

L17 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:611818 HCAPLUS
DOCUMENT NUMBER: 111:211818
TITLE: Empirical antibiotic therapy of **wounds** complicated by anaerobic nonclostridial infections
AUTHOR(S): Borisova, O. K.; Pavlova, M. V.; Yakovlev, V. P.; Kuleshov, S. E.
CORPORATE SOURCE: A. V. Vishnevskii Inst. Surg., Moscow, USSR
SOURCE: Antibiotiki i Khimioterapiya (1989), 34(9), 707-11
CODEN: ANKHEW; ISSN: 0235-2990
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB The antibiotic sensitivity to 14 antibacterial agents was tested in cultures of Bacteroides fragilis, B. melaninogenicus, and gram-pos. cocci isolated from nonclostridial anaerobic **wound** infections. While B. melaninogenicus was sensitive to all agents, B. fragilis was sensitive only to carbenicillin, lenomycetin, lincomycin, dioxidine, **metronidazole**, **tinidazole**, nitrazole, and erythromycin, and resistant to benzylpenicillin, ampicillin, cephazolin, tetracycline, cefotaxime, and cefuroxime.
IT **443-48-1 19387-91-8, Tinidazole**
RL: BIOL (Biological study)
(Bacteroides fragilis and B. melaninogenicus and cocci from **wound** anaerobic infections sensitivity to)